North America Microbiome Therapeutics Market Forecast to 2030

North America Microbiome Therapeutics Market Forecast to 2030

North America Microbiome Therapeutics Market Forecast to 2030 – Regional Analysis – by Type (Therapeutics and Procedure), Application (Metabolic Disorder and Obesity, C. Difficile Infection, Inflammatory Bowel Disease, and Others), and End User (Hospitals and Clinics, Ambulatory Surgical Centers, Homecare, and Others)

Send Enquiry
Item ID: BMIRE00029954 Category: Tag:

$2,840 – $4,440

Description

The North America microbiome therapeutics market was valued at US$ 161.64 million in 2022 and is expected to reach US$ 342.99 million by 2030; it is estimated to record a CAGR of 9.9% from 2022 to 2030.

Inflow of Funds to Ameliorate Microbiome Discovery Pipeline Drives North America Microbiome Therapeutics Market

Research has shown that imbalances or disruptions in the microbiome can contribute to various conditions, such as inflammatory bowel disease and obesity, as well as mental health disorders. The recognition of the microbiome’s role in overall health has generated significant interest in developing therapeutics to target and modulate the microbiome. Additionally, advancements in technology and research tools have made it easier to study and manipulate the microbiome. Next-generation sequencing and metagenomic analysis have allowed for a deeper understanding of microbial communities and their functions. The increased knowledge has opened up new possibilities for developing targeted therapies. Regulatory agencies such as the US Food and Drug Administration (FDA) have also shown a willingness to support the development of microbiome therapeutics. The FDA has established guidelines for FMT and has expressed interest in advancing the field through regulatory pathways that ensure safety and efficacy. All these factors combined have created a favorable investment climate for companies working in the field of microbiome therapeutics.

As strong clinical evidence becomes available, investors are beginning to take notice of microbiome modulator firms. The heightened funding provides companies with necessary resources to overcome the challenges associated with the high cost of development and production, ultimately driving the field forward.

North America Microbiome Therapeutics Market Overview

The increasing understanding of the importance of the human microbiome in maintaining health and preventing diseases has led researchers in the US to explore microbiome-based interventions as a promising approach to treating various conditions. Additionally, the dominance of this country in the North America microbiome therapeutics market is mainly attributed to its well-developed research infrastructure that favors the development of innovative treatments Further, the rising prevalence of chronic diseases such as obesity and inflammatory bowel disease has created a demand for innovative treatments, spurring the development of microbiome therapeutics. Technological advancements in gene sequencing and bioinformatics enable the study and alteration of the microbiome, facilitating the development of personalized microbiome-based interventions. The trend toward personalized medicine aligns well with tailormade microbiome therapeutics. Collaborations between academia, industry, and government organizations are also fueling research and development efforts, accelerating the translation of scientific discoveries into commercial products. Regulatory support and investment in the field further contribute to market growth, as regulatory bodies recognize the potential of microbiome therapeutics and provide guidance for their development and approval.

North America Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Million)

North America Microbiome Therapeutics Market Segmentation

The North America microbiome therapeutics market is segmented based on type, application, end user, and country.

Based on type, the North America microbiome therapeutics market is bifurcated into therapeutics and procedure. The procedure segment held a larger share in 2022. The therapeutics segment is further subsegmented into fecal microbiota transplantation (FMT), prebiotics & probiotics, and others.

By application, the North America microbiome therapeutics market is segmented into metabolic disorder and obesity, C. difficile infection, inflammatory bowel disease, and others. The C. difficile infection segment held the largest share in 2022.

By end user, the North America microbiome therapeutics market is hospitals and clinics, ambulatory surgical centers, homecare, and others. The hospitals and clinics segment held the largest share in 2022.

Based on country, the North America microbiome therapeutics market is segmented into the US, Canada, and Mexico. The US dominated the North America microbiome therapeutics market in 2022.

AOBiome Therapeutics Inc, Ferring Holdings SA, Finch Therapeutics Group Inc, Pendulum Therapeutics Inc, and Seres Therapeutics Inc are some of the leading companies operating in the North America microbiome therapeutics market.

Summary Info

Industry:

Pricing options:

, ,

Geographical coverage:

Year of Publication:

At 9.9% CAGR, North America Microbiome Therapeutics Market is Speculated to be Worth US$ 342.99 Million by 2030, Says the Research Team

According to the Research Team’ research, the North America microbiome therapeutics market was valued at US$ 161.64 million in 2022 and is expected to reach US$ 342.99 million by 2030, registering a CAGR of 9.9% from 2022 to 2030. Potential of gut microbiota in maintaining human health and inflow of funds to ameliorate microbiome discovery pipeline are among the critical factors attributed to the North America microbiome therapeutics market expansion.

Microbiome therapeutics are aimed at modifying the gut microbiome by using bacteriophages, bacteriocins, antibiotics, native or synthetic bacteria, or subtractive or modulatory treatment. By offering individualized, harmonized, dependable, and long-lasting therapy, this strategy can overcome the limitations of traditional therapies. The global therapeutics market has demonstrated its enormous economic potential. Studies have shown promising results in using microbiome therapeutics for conditions such as inflammatory bowel disease, obesity, and even mental health disorders. Ongoing research is also exploring the potential of microbiome-based interventions in areas of cancer treatment, diabetes management, and cardiovascular health. Further, the incidence of gastrointestinal illnesses increases with age, and the GI Alliance data from February 2021 estimates that almost 20 million Americans have chronic digestive diseases, and over 62 million Americans receive a diagnosis of gastrointestinal diseases each year. By understanding the intricate relationship between microbiome and disease development, scientists are developing personalized treatments that target the root cause of the problem rather than merely managing symptoms. As knowledge expands and technologies advance, microbiome therapeutics have the potential to become a cornerstone of modern medicine, offering hope for improved health outcomes for individuals affected by a range of diseases.

On the contrary, high cost of development and production hampers the growth of North America microbiome therapeutics market.

Based on type, the North America microbiome therapeutics market is bifurcated into therapeutics and procedure. The procedure segment held 98.2% share of the North America microbiome therapeutics market in 2022, amassing US$ 158.78 million. It is projected to garner US$ 332.31 million by 2030 to expand at 9.7% CAGR during 2022-2030. The therapeutics segment is further subsegmented into fecal microbiota transplantation (FMT), prebiotics & probiotics, and others.

By application, the North America microbiome therapeutics market is segmented into metabolic disorder and obesity, C. difficile infection, inflammatory bowel disease, and others. The C. difficile infection segment held 92.2% share of the North America microbiome therapeutics market in 2022, amassing US$ 148.96 million. It is projected to garner US$ 317.99 million by 2030 to expand at 9.9% CAGR during 2022-2030.

By end user, the North America microbiome therapeutics market is hospitals and clinics, ambulatory surgical centers, homecare, and others. The hospitals and clinics segment held 55.4% share of the North America microbiome therapeutics market in 2022, amassing US 89.53 million. It is projected to garner US$ 195.94 million by 2030 to expand at 10.3% CAGR during 2022-2030.

Based on country, the North America microbiome therapeutics market is segmented into US, Canada, and Mexico. The US held 83.2% share of North America microbiome therapeutics market in 2022, amassing US$ 134.50 million. It is projected to garner US$ 288.23 million by 2030 to expand at 10.0% CAGR during 2022-2030.

Key players operating in the North America microbiome therapeutics market are AOBiome Therapeutics Inc, Ferring Holdings SA, Finch Therapeutics Group Inc, Pendulum Therapeutics Inc, and Seres Therapeutics Inc, among others.

o Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America microbiome therapeutics market.
o Highlights key business priorities in order to assist companies to realign their business strategies.
o The key findings and recommendations highlight crucial progressive industry trends in North America microbiome therapeutics market, thereby allowing players across the value chain to develop effective long-term strategies.
o Develop modify business expansion plans by using substantial growth offering developed and emerging markets.
o Scrutinize in-depth North America market trends and outlook coupled with the factors driving the microbiome therapeutics market, as well as those hindering it.
o Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.

TABLE OF CONTENTS

1. Introduction
1.1 the Research Team Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Microbiome Therapeutics Market Landscape
4.1 Overview
4.2 North America PEST Analysis
5. North America Microbiome Therapeutics Market – Key Industry Dynamics
5.1 North America Microbiome Therapeutics Market – Key Industry Dynamics
5.2 Key Market Drivers
5.2.1 Potential of Gut Microbiota in Maintaining Human Health
5.2.2 Inflow of Funds to Ameliorate Microbiome Discovery Pipeline
5.3 Key Market Restraints
5.3.1 High Cost of Development and Production
5.4 Key Market Opportunities
5.4.1 Increasing R&D to Gain Better Understanding of Human Microbiome
5.5 Key Future Trends
5.5.1 Technological Advancement in Human Microbiome Therapeutics
5.6 Impact of Drivers and Restraints:
6. Microbiome Therapeutics Market – North America Market Analysis
7. North America Microbiome Therapeutics Market Analysis – Type
7.1 Therapeutics
7.1.1 Overview
7.1.2 Therapeutics Market, Revenue and Forecast to 2030 (US$ Thousand)
7.2 Procedure
7.2.1 Overview
7.2.2 Procedure Market, Revenue and Forecast to 2030 (US$ Thousand)
8. North America Microbiome Therapeutics Market Analysis – Application
8.1 Metabolic Disorder and Obesity
8.1.1 Overview
8.1.2 Metabolic Disorder and Obesity Market, Revenue and Forecast to 2030 (US$ Thousand)
8.2 C. Difficile Infection (CDI)
8.2.1 Overview
8.2.2 C. Difficile Infection (CDI) Market, Revenue and Forecast to 2030 (US$ Thousand)
8.3 Inflammatory Bowel Disease
8.3.1 Overview
8.3.2 Inflammatory Bowel Disease Market, Revenue and Forecast to 2030 (US$ Thousand)
8.4 Others
8.4.1 Overview
8.4.2 Others Market, Revenue and Forecast to 2030 (US$ Thousand)
9. North America Microbiome Therapeutics Market Analysis – End User
9.1 Hospitals and Clinics
9.1.1 Overview
9.1.2 Hospitals and Clinics Market, Revenue and Forecast to 2030 (US$ Thousand)
9.2 Ambulatory Surgical Centers
9.2.1 Overview
9.2.2 Ambulatory Surgical Centers Market, Revenue and Forecast to 2030 (US$ Thousand)
9.3 Homecare
9.3.1 Overview
9.3.2 Homecare Market, Revenue and Forecast to 2030 (US$ Thousand)
9.4 Others
9.4.1 Overview
9.4.2 Others Market, Revenue and Forecast to 2030 (US$ Thousand)
10. North America Microbiome Therapeutics Market – Country Analysis
10.1 North America Microbiome Therapeutics Market Revenue and Forecasts and Analysis – By Country
10.1.1 North America Microbiome Therapeutics Market Revenue and Forecasts and Analysis – By Country
10.1.2 US
10.1.2.1 US: North America Microbiome Therapeutics Market Revenue and Forecasts to 2030 (US$ Thousands)
10.1.2.2 US: North America Microbiome Therapeutics Market Breakdown by Type
10.1.2.2.1 US North America Microbiome Therapeutics Market Breakdown by Therapeutics
10.1.2.3 US: North America Microbiome Therapeutics Market Breakdown by Application
10.1.2.4 US: North America Microbiome Therapeutics Market Breakdown by End User
10.1.3 Canada
10.1.3.1 Canada: North America Microbiome Therapeutics Market Revenue and Forecasts to 2030 (US$ Thousands)
10.1.3.2 Canada: North America Microbiome Therapeutics Market Breakdown by Type
10.1.3.2.1 Canada North America Microbiome Therapeutics Market Breakdown by Therapeutics
10.1.3.3 Canada: North America Microbiome Therapeutics Market Breakdown by Application
10.1.3.4 Canada: North America Microbiome Therapeutics Market Breakdown by End User
10.1.4 Mexico
10.1.4.1 Mexico: North America Microbiome Therapeutics Market Revenue and Forecasts to 2030 (US$ Thousands)
10.1.4.2 Mexico: North America Microbiome Therapeutics Market Breakdown by Type
10.1.4.2.1 Mexico: North America Microbiome Therapeutics Market Breakdown by Therapeutics
10.1.4.3 Mexico: North America Microbiome Therapeutics Market Breakdown by Application
10.1.4.4 Mexico: North America Microbiome Therapeutics Market Breakdown by End User
11. Industry Landscape
11.1 Overview
11.2 Growth Strategies in North America Microbiome Therapeutics Market
12. Company Profiles
12.1 Ferring Holdings SA
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Vedanta Biosciences Inc
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Finch Therapeutics Group Inc
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Pendulum Therapeutics Inc
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Seres Therapeutics Inc
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 AOBiome Therapeutics Inc
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
13. Appendix
13.1 About the Research Team
13.2 Glossary of Terms

LIST OF TABLES

Table 1. North America Microbiome Therapeutics Market Segmentation
Table 2. North America Microbiome Therapeutics Market Revenue and Forecasts to 2030 (US$ Thousand) – Type
Table 3. North America Microbiome Therapeutics Market Revenue and Forecasts to 2030 (US$ Thousand) – Therapeutics
Table 4. North America Microbiome Therapeutics Market Revenue and Forecasts to 2030 (US$ Thousand) – Application
Table 5. North America Microbiome Therapeutics Market Revenue and Forecasts to 2030 (US$ Thousand) – End User
Table 6. North America Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) – By Country
Table 7. US: North America Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) – By Type
Table 8. US: North America Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) – By Therapeutics
Table 9. US: North America Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) – By Application
Table 10. US: North America Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) – By End User
Table 11. Canada: North America Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) – By Type
Table 12. Canada: North America Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) – By Therapeutics
Table 13. Canada: North America Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) – By Application
Table 14. Canada: North America Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) – By End User
Table 15. Mexico: North America Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) – By Type
Table 16. Mexico: North America Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) – By Therapeutics
Table 17. Mexico: North America Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) – By Application
Table 18. Mexico: North America Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) – By End User
Table 19. Recent Growth Strategies in North America Microbiome Therapeutics Market
Table 20. Glossary of Terms, North America Microbiome Therapeutics Market

LIST OF FIGURES

Figure 1. North America Microbiome Therapeutics Market Segmentation, By Country
Figure 2. North America PEST Analysis
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. North America Microbiome Therapeutics Market Revenue (US$ Thousand), 2022 – 2030
Figure 5. North America Microbiome Therapeutics Market Share (%) – Type, 2022 and 2030
Figure 6. Therapeutics Market Revenue and Forecasts to 2030 (US$ Thousand)
Figure 7. Procedure Market Revenue and Forecasts to 2030 (US$ Thousand)
Figure 8. North America Microbiome Therapeutics Market Share (%) – Application, 2022 and 2030
Figure 9. Metabolic Disorder and Obesity Market Revenue and Forecasts to 2030 (US$ Thousand)
Figure 10. C. Difficile Infection (CDI) Market Revenue and Forecasts to 2030 (US$ Thousand)
Figure 11. Inflammatory Bowel Disease Market Revenue and Forecasts to 2030 (US$ Thousand)
Figure 12. Others Market Revenue and Forecasts to 2030 (US$ Thousand)
Figure 13. North America Microbiome Therapeutics Market Share (%) – End User, 2022 and 2030
Figure 14. Hospitals and Clinics Market Revenue and Forecasts to 2030 (US$ Thousand)
Figure 15. Ambulatory Surgical Centers Market Revenue and Forecasts to 2030 (US$ Thousand)
Figure 16. Homecare Market Revenue and Forecasts to 2030 (US$ Thousand)
Figure 17. Others Market Revenue and Forecasts to 2030 (US$ Thousand)
Figure 18. North America Microbiome Therapeutics Market Breakdown by Key Countries – Revenue (2022) (US$ Thousand)
Figure 19. North America Microbiome Therapeutics Market Breakdown by Key Countries, 2022 and 2030 (%)
Figure 20. US: North America Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands)
Figure 21. Canada: North America Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands)
Figure 22. Mexico: North America Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands)

The List of Companies – North America Microbiome Therapeutics Market

1. AOBiome Therapeutics Inc
2. Ferring Holdings SA
3. Finch Therapeutics Group Inc
4. Pendulum Therapeutics Inc
5. Seres Therapeutics Inc
6. Vedanta Biosciences, Inc.

Reviews

There are no reviews yet.

Be the first to review “North America Microbiome Therapeutics Market Forecast to 2030”